{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:58:06Z","timestamp":1784365086376,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1111\/dsu.12049","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T20:24:35Z","timestamp":1360009475000},"page":"634-645","source":"Crossref","is-referenced-by-count":60,"title":["Capecitabine to Reduce Nonmelanoma Skin Carcinoma Burden in Solid Organ Transplant Recipients"],"prefix":"10.1097","volume":"39","author":[{"given":"Bart","family":"Endrizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehana L.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"4","key":"R1-17-20210206","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00019053-200725040-00002","article-title":"Measuring patientreported outcomes in solid organ transplant recipients: an overview of instruments developed to date.","volume":"25","author":"Cleemput","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"R2-17-20210206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00063030-200014050-00004","article-title":"Skin cancer risk associated with immunosuppressive therapy in organ transplant recipients: epidemiology and proposed mechanisms.","volume":"14","author":"Kuijken","year":"2000","journal-title":"BioDrugs"},{"issue":"11","key":"R3-17-20210206","first-page":"663","article-title":"Cutaneous cancers after organ transplantation.","volume":"62","author":"Quatresooz","year":"2007","journal-title":"Rev Med Liege"},{"issue":"2","key":"R4-17-20210206","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2002.20.2.582","article-title":"Dose escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"R5-17-20210206","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation.","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"R6-17-20210206","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2007.06174.x","article-title":"Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients.","volume":"6","author":"Herman","year":"2007","journal-title":"Skinmed"},{"key":"R7-17-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.125579","article-title":"Skin Cancer in organ transplant recipients. Epidemiology, pathogenesis and management.","volume":"47","author":"Berg","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R8-17-20210206","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after solid organ transplantation.","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"R9-17-20210206","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archdermatol.2009.377","article-title":"Incidence and clinical predictors of subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer.","volume":"146","author":"Tessari","year":"2010","journal-title":"Arch Dermatol"},{"key":"R10-17-20210206","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1600-0625.2010.01086.x","article-title":"Organ transplantation and skin cancer: basic problems and new perspectives.","volume":"19","author":"Hofbauer","year":"2010","journal-title":"Exp Dermatol"},{"key":"R11-17-20210206","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue.","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"R12-17-20210206","first-page":"33","article-title":"Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.","volume":"17","author":"Mori","year":"2000","journal-title":"Int J Oncol"},{"issue":"1","key":"R13-17-20210206","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00003495-199958010-00006","article-title":"Capecitabine.","volume":"58","author":"Dooley","year":"1999","journal-title":"Drugs"},{"key":"R14-17-20210206","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1191\/1078155205jp163cr","article-title":"Actinic keratosis and Capecitabine therapy.","volume":"11","author":"Higa","year":"2005","journal-title":"J Oncol Pharm Practice"},{"key":"R15-17-20210206","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/archderm.140.3.367","article-title":"Inflammation of actinic keratoses during Capecitabine therapy.","volume":"140","author":"Lewis","year":"2004","journal-title":"Arch Dermatol"},{"key":"R17-17-20210206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/07357909509094459","article-title":"Cisplatin and 5fluorouracil for metastatic squamous cell carcinoma from unknown primary.","volume":"13","author":"Khansur","year":"1995","journal-title":"Cancer Invest"},{"key":"R18-17-20210206","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000421-200004000-00015","article-title":"Oral 5fluorouracil in squamous cell carcinoma of the skin in the aged.","volume":"23","author":"Cartei","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"R19-17-20210206","first-page":"685","article-title":"Positive correlation between the effect of capecitabine and deoxyfluorodine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumor in human cancer xenografts.","volume":"58","author":"Ishikawa","year":"1998","journal-title":"Cancer Res"},{"key":"R20-17-20210206","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y","article-title":"Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5fluorouracil, and bleomycin.","volume":"66","author":"Sadek","year":"1990","journal-title":"Cancer"},{"issue":"5","key":"R22-17-20210206","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00432-004-0656-6","article-title":"Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin.","volume":"131","author":"Wollina","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"R23-17-20210206","first-page":"134","article-title":"Safety of chronic lowdose capecitabine as maintanence therapy in gastrointestinal cancers.","volume":"3","author":"Son","year":"2009","journal-title":"Gastrointest Cancer Res"},{"issue":"10","key":"R24-17-20210206","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1524-4725.2009.01277.x","article-title":"Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine.","volume":"35","author":"Endrizzi","year":"2009","journal-title":"Dermatol Surg"},{"issue":"4","key":"R25-17-20210206","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1399-0012.2010.01348.x","article-title":"Capecitabine for skin cancer prevention in solid organ transplant recipients.","volume":"25","author":"Jirakulaporn","year":"2011","journal-title":"Clin Transplant"},{"key":"R27-17-20210206","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of bodysurface area.","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"R28-17-20210206","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jjco\/hyl134","article-title":"Combination chemotherapy with Capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.","volume":"37","author":"Lee","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"R29-17-20210206","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00007890-199603150-00008","article-title":"The risk of skin cancer in renal transplant recipients in Queensland, Australia: a followup study.","volume":"61","author":"Bouwes Bavink","year":"1996","journal-title":"Transplantation"},{"key":"R30-17-20210206","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic lesions during acitretin therapy in renal transplant recipients: a doubleblinded placebo controlled study.","volume":"13","author":"Bouwes Bavink","year":"1995","journal-title":"J Clin Oncol"},{"key":"R31-17-20210206","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2133.2005.06347.x","article-title":"Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials.","volume":"152","author":"Chen","year":"2005","journal-title":"Br J Dermatol"},{"key":"R32-17-20210206","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of nonmelanoma skin cancers in renal transplant recipients.","volume":"43","author":"George","year":"2002","journal-title":"Australas J Dermatol"},{"key":"R33-17-20210206","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1067\/S0190-9622(03)01831-0","article-title":"Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomised trial comparing two doses of acitretin.","volume":"49","author":"De Sevaux","year":"2003","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1111\/dsu.12049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:07:25Z","timestamp":1620979645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201304000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1111\/dsu.12049","relation":{},"ISSN":["1076-0512"],"issn-type":[{"value":"1076-0512","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}